UroGen Pharma Ltd. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
UroGen Pharma Ltd. (URGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $1.05 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2023-03-24
- UroGen Pharma Ltd. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $1.05M, a 53.53% decline from fiscal 2021.
- UroGen Pharma Ltd. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was $2.26M, a 22.99% decline from fiscal 2020.
- UroGen Pharma Ltd. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2020 was $2.94M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2022-12-31 | $1.05M 10-K · filed 2023-03-24 |
| 2021-12-31 | $2.26M 10-K · filed 2023-03-24 |
| 2020-12-31 | $2.94M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |